Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Donna S. Neuberg, D.Sc.

Co-Author

This page shows the publications co-authored by Donna Neuberg and Robert Lindsley.
Connection Strength

1.665
  1. Prediction of Life-threatening and Disabling Bleeding in Patients with AML Receiving Intensive Induction Chemotherapy. Blood Adv. 2022 Jan 26.
    View in: PubMed
    Score: 0.246
  2. The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood. 2021 09 09; 138(10):898-911.
    View in: PubMed
    Score: 0.239
  3. Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 2020 12 24; 136(26):3070-3081.
    View in: PubMed
    Score: 0.228
  4. Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome. Blood. 2020 Aug 17.
    View in: PubMed
    Score: 0.222
  5. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017 02 09; 376(6):536-547.
    View in: PubMed
    Score: 0.174
  6. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
    View in: PubMed
    Score: 0.151
  7. Genomic profiling of a randomized trial of interferon-a vs hydroxyurea in MPN reveals mutation-specific responses. Blood Adv. 2022 Apr 12; 6(7):2107-2119.
    View in: PubMed
    Score: 0.062
  8. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022 Mar 15; 1-8.
    View in: PubMed
    Score: 0.062
  9. Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction. Am J Hematol. 2021 07 01; 96(7):E259-E262.
    View in: PubMed
    Score: 0.058
  10. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
    View in: PubMed
    Score: 0.053
  11. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019 08 09; 365(6453):599-604.
    View in: PubMed
    Score: 0.052
  12. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
    View in: PubMed
    Score: 0.043
  13. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 Dec 25; 371(26):2488-98.
    View in: PubMed
    Score: 0.037
  14. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.